Table 1.
Upcoming targeted therapies and their current clinical trials
| Compound | Phase | Title | ClinicalTrials.gov Identifier |
|---|---|---|---|
| Margetuximab | 2 | Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients with Relapsed or Refractory Advanced Breast Cancer | NCT01828021 |
| Margetuximab | 3 | Margetuximab Plus Chemotherapy vs. Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer (SOPHIA) | NCT02492711 |
| Margetuximab | N/A | Margetuximab Expanded Access Program | NCT03133988 |
| DS-8201a | 2 | DS-8201a in HER2+ Breast Cancer (DESTINY-Breast01) | NCT03248492 |
| DS-8201a | 3 | DS-8201a in Pretreated HER2+ Breast Cancer That Cannot be Surgically Removed or Has Spread (DESTINY-Breast02) | NCT03523585 |
| DS-8201a | 3 | DS-8201a Versus T-DM1 for HER2+, Unresectable and/or Metastatic Breast Cancer Previously Treated with Trastuzumab and Taxane (DESTINY-Breast03) | NCT03529110 |
| DS-8201a | 3 | Trastuzumab Deruxtecan (DS-8201a) Versus Investigator’s Choice for HER-Low Breast Cancer That Has Spread or Cannot Be Surgically Removed (DESTINY-Breast04) | NCT03734029 |
| DS-8201a | 1 | Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval in HER2-Expressive Breast Cancer | NCT03366428 |
| DS-8201a | 1 | Trastuzumab Deruxtecan (DS-8201a) with Nivolumab in Advanced Breast and Urothelial Cancer | NCT03523572 |
| DS-8201a | 1 | DS-8201a in Patients with Cancer That Tests Positive for HER2 Protein | NCT03368196 |
| DS-8201a | 1 | DS-8201a and Pembrolizumab in Participants with Locally Advanced/Metastatic Breast Cancer or Non-Small Cell Lung Cancer | NCT04042701 |
| Tucatinib | 1b/2 | Tucatinib, Palbociclib, and Letrozole in Metastatic Hormone Receptor-Positive and HER2-Positive Breast Cancer | NCT03054363 |
| Tucatinib | 1 | A Study of Tucatinib (ONT-380) Combined with Capecitabine and/or Trastuzumab in HER2+ Metastatic Breast Cancer | NCT02025192 |
| Tucatinib | 2 | A Study of Tucatinib vs. Placebo in Combination with Capecitabine & Trastuzumab in Patients with Advanced HER2+ Breast Cancer (HER2CLIMB) | NCT02614794 |
| Tucatinib | 3 | A Study of Tucatinib vs. Placebo in Combination with Ado-Trastuzumab Emtansine (T-DM1) for Patients with Advanced or Metastatic HER2+ Breast Cancer | NCT03975647 |
| Tucatinib | 1 | Tucatinib + Abemaciclib + Herceptin for HER2+ MBC | NCT03846583 |
| Tucatinib | 1 | A Study of Tucatinib (ONT-380) Combined with Ado-Trastuzumab Emtansine (T-DM1) in Patients with HER2+ Breast Cancer | NCT01983501 |
| Tucatinib | 2 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ Leptomeningeal Disease (LMD) | NCT03501979 |
| Tucatinib | N/A | Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer | NCT03424473 |